<SEC-DOCUMENT>0001571049-16-017329.txt : 20160810
<SEC-HEADER>0001571049-16-017329.hdr.sgml : 20160810
<ACCEPTANCE-DATETIME>20160810161524
ACCESSION NUMBER:		0001571049-16-017329
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160810
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160810
DATE AS OF CHANGE:		20160810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		161821711

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1601982_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 18pt"><B>FORM 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>of the
Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Date of
Report (Date of earliest event reported): August 10, 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 24pt"><B>CYCLACEL
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(State
                                    or other jurisdiction</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>of
        incorporation)</B></FONT></P></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Commission File Number)</B></FONT></TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(IRS
                                    Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Address
of principal executive offices and zip code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<I>see </I>General
Instruction A.2. below): </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt"><B>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="width: 96%"><FONT STYLE="font-size: 10pt"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 2.02 Results of Operations and Financial Condition.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information set forth under this &ldquo;Item
2.02. Results of Operations and Financial Condition,&rdquo; including the exhibit attached hereto, shall not be deemed &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference
into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such
filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attached as Exhibit 99.1 is a copy of a
press release of Cyclacel Pharmaceuticals, Inc. (the &ldquo;<B>Company</B>&rdquo;), dated August 10, 2016, announcing certain financial
results for the second quarter ended June 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company will conduct a conference call
to review its financial results on August 10, 2016, at 4:30 p.m., Eastern Time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 10%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Exhibit</B><BR>
    <B>Number</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 89%; text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press release announcing financial results for the second quarter ended June 30, 2016, dated August 10, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 44%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Executive Vice President&mdash;Finance,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: August 10, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1601982_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font: 11pt Calibri, Helvetica, Sans-Serif"><IMG SRC="ex99-1_logo.jpg" ALT=""></TD>
    <TD STYLE="width: 50%; font: 11pt Calibri, Helvetica, Sans-Serif; text-align: right; vertical-align: bottom"><FONT STYLE="font-family: Arial, Helvetica, Sans-Serif; font-size: 10pt">Cyclacel Pharmaceuticals, Inc.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><IMG SRC="ex99-1_logo1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><B>CYCLACEL PHARMACEUTICALS
REPORTS 2<SUP>ND</SUP> QUARTER 2016 FINANCIAL RESULTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center; background-color: white"><B><I>Conference
Call Scheduled August 10, 2016 at 4:30 p.m. EDT </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>BERKELEY HEIGHTS, N.J., Aug. 10,
2016</B> -- Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (&quot;Cyclacel&quot; or the &quot;Company&quot;), a
biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer
and other serious disorders, today reported financial results and business highlights for the second quarter ended June 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">The Company's net loss applicable
to common shareholders for the second quarter ended June 30, 2016 was $3.0 million, or $1.01 per basic and diluted share, compared
to net loss applicable to common shareholders of $3.4 million, or $1.19 per basic and diluted share for the second quarter ended
June 30, 2015. As of June 30, 2016, cash and cash equivalents totaled $15.9 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&quot;Subsequent to the end of the
quarter, we achieved a key milestone in our acute myeloid leukemia (AML) SEAMLESS Phase 3 study,&rdquo; said Spiro Rombotis, President
and Chief Executive Officer of Cyclacel. &ldquo;The required number of events has been reached and preparations for final analysis
and reporting of SEAMLESS outcomes are underway. Over the next several weeks, we will complete data cleaning and validation operations
after which the database will be transferred to our statistical analysis vendor. We will subsequently report outcomes for the primary
(overall survival) and secondary endpoints and determination of submissibility of the SEAMLESS data set to regulatory authorities
in Europe and the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">In our DNA damage response program,
durable antitumor activity was reported at an oral presentation at the 2016 ASCO Annual Meeting with a combination of sapacitabine
and seliciclib, our CDK2/9 inhibitor, in heavily pretreated patients with breast, ovarian and pancreatic cancers who tested positive
for BRCA mutations. A disease control rate of 35.6% was observed, with ongoing responding patients achieving treatment durations
exceeding 1 and 4.7 years, respectively. We continue to enroll patients with solid tumors in a first-in-human, Phase 1 study of
CYC065, our second-generation CDK2/9 inhibitor.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>BUSINESS HIGHLIGHTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>SEAMLESS study </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Phase 3 study of oral sapacitabine capsules alternating with intravenous decitabine compared to
decitabine alone, as first-line treatment in patients aged 70 years or older with AML who are unfit or refused intensive chemotherapy,
reached the number of events required for final analysis.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Preparations are underway for final analysis of study data.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>DNA damage response program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD>Oral presentation of data at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD>Phase 1 combination of sapacitabine and seliciclib as orally-administered treatment in 67 heavily-pretreated patients. Antitumor
activity in subgroup of 45 patients with breast, ovarian and pancreatic cancers who tested positive
for BRCA mutations. Disease control rate of 35.6% (1 CR, 5 PR and 10 SD). No CR or PR observed in BRCA negative patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0 0pt 0.25in; background-color: white"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify">Ongoing extension cohort in BRCA positive patients with breast cancer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>Cyclin dependent kinase (CDK)
inhibitor program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify">Continued recruitment in Phase 1, first-in-human trial of CYC065, a CDK2/9 inhibitor, to evaluate
safety, tolerability and pharmacokinetics in patients with solid tumors and lymphomas.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B><I>Corporate</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Received notification from the Listing Qualifications Staff of NASDAQ that the Company regained
compliance with the minimum bid price rule for continued listing on The NASDAQ Capital Market.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Effected a one-for-twelve reverse stock split of the Company&#8217;s outstanding shares of common
stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Entered into an&nbsp;At Market&nbsp;Issuance Sales Agreement with&nbsp;FBR Capital Markets &amp;
Co. under which the Company may, from time to time, sell shares of the Company&#8217;s common stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 12pt">&#183;</FONT></TD><TD STYLE="text-align: justify">Terminated Controlled Equity Offering<SUP>SM</SUP> sales agreement with Cantor Fitzgerald &amp;
Co.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>KEY UPCOMING MILESTONES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>SEAMLESS
study</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Study database locked in preparation for final data analysis.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD STYLE="text-align: justify">Report top-line data and determination of submissibility to regulatory authorities, anticipated
in the fourth quarter 2016.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Progress the Paediatric Investigation Plan for sapacitabine with the European Medicines Agency.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>DNA damage response program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify">Progress Phase 1 sapacitabine and seliciclib extension cohort in a breast cancer patient population
enriched for BRCA mutations.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify">Plan to add Phase 1, part 3 to include BRCA mutation positive, pancreatic and ovarian cancer patients.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>CDK Inhibitor Program</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD STYLE="text-align: justify">Report top-line results of the CYC065 Phase 1 trial in patients with solid tumors and lymphomas.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD>Report data when available from ongoing investigator sponsored trials (ISTs) evaluating seliciclib in patients with Cushing&#8217;s
disease and rheumatoid arthritis. Additionally, seliciclib is being evaluated in cystic fibrosis though a license and supply agreement
with ManRos Therapeutics.<B><I> </I></B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>Sapacitabine in myelodysplastic
syndromes (MDS): </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD>Plan a Phase 1/2 trial of sapacitabine in combination with other agents to determine safety and tolerability.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&#183;</FONT></TD><TD>Plan a Phase 2 randomized controlled trial (RCT) of sapacitabine in combination with other agents following review of all relevant
clinical data with mature follow-up.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>SECOND QUARTER 2016 FINANCIAL RESULTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>Grant Revenue</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Revenue for the three months ended
June 30, 2016 was $0.2 million, compared to $0.3 million for the same period of the previous year. The revenue is related to previously
awarded grants from the UK government being recognized over the period to progress CYC065 to IND and complete IND-directed preclinical
development of CYC140, a novel, orally available, Polo-Like Kinase 1 (PLK 1) inhibitor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Research and development expenses
were $2.6 million for the three months ended June 30, 2016 and $2.6 million for the three months ended June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B><I>General and Administrative Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">General and administrative expenses
were $1.3 million for the three months ended June 30, 2016 and $1.3 million for the three months ended June 30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Based on current plans, the Company
estimates that it has capital resources to reach beyond the final analysis of SEAMLESS and continue existing programs through the
first quarter of 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>CONFERENCE CALL AND WEBCAST INFORMATION:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Cyclacel will conduct a conference
call on August 10, 2016 at 4:30 p.m. Eastern Time to review the second quarter 2016 results. Conference call and webcast details
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">Conference call information:</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">US/Canada call: (877) 493-9121/ international call: (973) 582-2750</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">US/Canada archive: (800) 585-8367 / international archive:
(404) 537-3406</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">Code for live and archived conference call is 59985383</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">For the live and archived webcast,
please visit the Corporate Presentations and Events page on the Cyclacel website at <FONT STYLE="color: blue"><U>www.cyclacel.com</U></FONT>.
The webcast will be archived for 90 days and the audio replay for 7 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>About Cyclacel Pharmaceuticals,
Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">Cyclacel Pharmaceuticals is a clinical-stage
biopharmaceutical company using cell cycle control and DNA damage response biology to develop innovative, targeted medicines for
cancer and other proliferative diseases. The SEAMLESS randomized Phase 3 trial of sapacitabine as front-line treatment for AML
in the elderly under an SPA with FDA has completed enrollment. Cyclacel's pipeline includes an oral combination of seliciclib (CDK2/9
inhibitor) and sapacitabine in Phase 1 in advanced solid tumors, including patients with BRCA mutations; sapacitabine in Phase
2 in MDS; and CYC065 (CDK2/9 inhibitor) in Phase 1 in solid tumors and lymphomas with potential utility
based on preclinical data in other hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical
business focused in hematology and oncology based on a pipeline of novel drug candidates. Please visit <FONT STYLE="color: blue"><U>www.cyclacel.com</U></FONT>
for more information.</P>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;&nbsp;</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white"><B>FORWARD LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; background-color: white">This news release contains certain
forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from
historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements
include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates,
the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and
plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product
candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale
or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates,
the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on
collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider
statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot;
&quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot; &quot;expects,&quot; &quot;plans,&quot;
&quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot; &quot;designed,&quot; &quot;goal,&quot;
or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description
of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic
and other filings we file with the Securities and Exchange Commission and are available at <FONT STYLE="color: blue"><U>www.sec.gov</U></FONT>.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><B>CONTACTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font: 11pt Calibri, Helvetica, Sans-Serif">Company:</TD>
    <TD STYLE="width: 80%; font: 11pt Calibri, Helvetica, Sans-Serif">Paul McBarron, (908) 517-7330, <FONT STYLE="color: blue"><U>pmcbarron@cyclacel.com</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif">Investor Relations:</TD>
    <TD STYLE="font: 11pt Calibri, Helvetica, Sans-Serif">Russo Partners LLC, Alexander Fudukidis, (646) 942-5632, </TD></TR>
</TABLE>
<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; color: blue"><U>alex.fudukidis@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify">&copy; Copyright 2016 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. The Cyclacel logo and Cyclacel&reg; are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS,&nbsp;INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>(In $000s, except share and per share
amounts)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>(Unaudited)</B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three&nbsp;Months&nbsp;Ended<BR> June 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Six&nbsp;Months&nbsp;Ended<BR> June 30,</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Revenues:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 48%; font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Grant revenue</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">296</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">222</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">808</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">361</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,580</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,637</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,922</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,136</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,333</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,345</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,801</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,729</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,913</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,982</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">9,723</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,865</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Operating loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,617</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(3,760</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(8,915</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,504</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Change in valuation of financial instruments associated with stock purchase agreement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(24</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&mdash;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Foreign exchange (loss) gain</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(195</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">138</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(573</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">318</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Interest income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">13</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Other income, net</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">62</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">82</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">38</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Total other income (expense)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(135</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">169</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(512</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">379</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Loss before taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,752</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,591</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(9,427</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,125</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Income tax benefit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">405</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">626</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,168</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,119</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Net loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(3,347</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,965</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(8,259</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(6,006</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Dividend on convertible exchangeable preferred shares</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(50</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(100</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(100</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.25pt; text-indent: -10pt; padding-left: 10pt">Net loss applicable to common shareholders</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(3,397</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(3,015</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(8,359</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(6,106</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">Basic and diluted earnings per common share:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: -10pt; padding-left: 10pt">Net loss per share&thinsp;&ndash;&thinsp;basic and diluted</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(1.19</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(1.01</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(3.32</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">(2.05</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 2.25pt; text-indent: -10pt; padding-left: 10pt">Weighted average common shares outstanding</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,865,707</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">3,000,192</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,520,897</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">2,982,508</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center; font-family: Calibri, Helvetica, Sans-Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><B>(In $000s, except share, per share,
and liquidation preference amounts) </B></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center">December 31,</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold">&nbsp;</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 8pt; font-weight: bold; text-align: center">June 30,</TD><TD NOWRAP STYLE="font-size: 8pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</TD><TD STYLE="padding-bottom: 1pt; font-size: 8pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-size: 8pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 8pt; font-weight: bold; text-align: center">(Unaudited)</TD><TD STYLE="font-size: 8pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 74%; font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">20,440</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">15,931</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,051</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,762</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Current assets of discontinued operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">24,566</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,768</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Property, plant and equipment (net)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">198</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">109</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.25pt; text-indent: -0.1in; padding-left: 0.35in">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">24,764</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">18,877</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,940</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,898</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accrued and other current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,738</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,592</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 16.2pt">Current liabilities of discontinued operations</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">75</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,753</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,565</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; text-indent: -0.1in; padding-left: 0.1in">Other liabilities</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">176</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">150</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -0.1in; padding-left: 0.35in">Total liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,929</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,715</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 0">Total stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,835</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,162</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 16.2pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">24,764</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">18,877</TD><TD STYLE="padding-bottom: 2.25pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><B>Source: Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1 "U P$1  (1 0,1 ?_$ *P  0 " P$! 0$!
M       ("04'"@8$ 0(# 0$  04! 0$             !@,$!0<("0$"$
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ML5+V:)EX1Z_>2=8?5PIH\$G2+8@N53JI*J%0.BI6TP     .@!Z  >@  ?@
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M?U+FWMK_ /XU]7^GZ7S>&GK:K?&GQ/B-?@?'^#\='X?Q/;^)\3VR_'^+[/\
M9^/[/3L[/R]O3IZ<YGE]3U&];5ZVHZM5[WOUO?K>_C?K>NR8?2])?;Z?0TC3
MIMITVZ:;=+6M:W2WA7T<_%5*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ
%2G%*_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_logo1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ %P), P$1  (1 0,1 ?_$ '0  0 # 0 " P
M       '" D& P4! @H! 0                     0   % P,# P,"! <!
M      $" P0%  8'$=07$E>7(1,(,2(406$R(Q4)4:&R<R0T%C41 0
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M.^O%Q;<:C$IW%*-46DB_9M-4F/YJ;=15(Z[9F!$A4 =5.CJ'[A&@[F@@;/\
M@QMGBW;;@EKJD;06MB[HZ\&$I&,&4BO_ %",;/4&J9D'Y@0Z"*.P4U'7U( "
M @(T$BV#;MR6O;R43==\2.0I<CMXN>Y)2)B85VJ@X5ZV[,6,*B@Q*FR)]A3
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BM+G;QE);F@^W.J'3U<39T_BZ>GC.2ZOIKKT_D_P_O0?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
